Faculty Profiles - SONE, Hirohito

Papers - SONE, Hirohito

Division display 21 - 40 of about 618 ／ All the affair displays >>

心血管疾患 2型糖尿病およびMASLDの寛解による心血管疾患(CVD)発症率の変化

松林泰弘, 藤原和哉, 山田万祐子, 佐藤隆明, 山本正彦, 石黒創, 大澤妙子, 北澤勝, 山田貴穂, 曽根博仁

糖尿病合併症 38 ( Suppl.1 ) 143 - 143 2024.9

心血管疾患糖尿病の寛解が心血管疾患発症に及ぼす影響の検討

島山千弥, 藤原和哉, 大江桃子, 上神洋平, 滝澤大輝, 佐藤隆明, 鈴木浩史, 北澤勝, 松林泰弘, 山田貴穂, 児玉暁, 曽根博仁

糖尿病合併症 38 ( Suppl.1 ) 143 - 143 2024.9

網膜症・動脈硬化1 糖尿病・冠動脈疾患・脳血管疾患の既往及び組み合わせがその後の心血管疾患リスクへ及ぼす影響の検討

大江桃子, 藤原和哉, 山田万祐子, 山本正彦, 大澤妙子, 北澤勝, 松林泰弘, 佐藤隆明, 矢口雄大, 山田貴穂, 曽根博仁

糖尿病合併症 38 ( Suppl.1 ) 154 - 154 2024.9

日本人健常妊婦における妊娠初期の栄養摂取量と妊娠中の体重増加量および妊娠転帰への影響の検討

谷内洋子, 生魚薫, 堀川千嘉, 森川咲子, 治田麻理子, 曽根博仁

New Diet Therapy 40 ( 2 ) 167 - 167 2024.9

Robust growth hormone responses to GH-releasing peptide 2 in adolescents. International journal

Takanori Onuki, Tadokoro Hiroaki, Kentaro Sawano, Nao Shibata, Hiromi Nyuzuki, Yohei Ogawa, Masayasu Okada, Hirohito Sone, Keisuke Nagasaki

Journal of pediatric endocrinology & metabolism : JPEM 37 ( 8 ) 730 - 733 2024.8

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: GH-releasing peptide-2 (GHRP2) can be used for provocative growth hormone testing (GHT). Since it acts as a powerful stimulus for GH secretion, cut-off peak GH level in GHRP2 loading test (GHRP2T) is higher than in other GHT. Nevertheless, data on response at adolescents are limited. This report aimed to investigate peak GH levels in GHRP2T in adolescents. METHODS: Clinical data of adolescents after onset of puberty who underwent GHRP2T at our institution from May 2010 to March 2023 were collected retrospectively. Subjects were classified into three groups according to underlying diseases. RESULTS: A total of 23 patients were included: 12 in organic or genetic GHD (o/gGHD) group, three in idiopathic GHD (iGHD) group, and eight in short stature (SS) group. The median GH peak levels were 3.4 ng/mL in o/gGHD group, 88.9 ng/mL in iGHD group, and 90.1 ng/mL in SS group, indicating a robust response of GH peak levels in iGHD and SS groups. Two patients exceeded the cut-off for GHRP2T but below for other GHT, indicating the current cut-off for GHRP2T may miss some GHD patients. CONCLUSIONS: The GH response to GHRP2T in adolescents except the o/gGHD group may be robustly responsive. For the correct diagnosis of GHD, the cut-off peak GH levels in GHRP2T in adolescents may require revisiting.

DOI： 10.1515/jpem-2024-0115

PubMed

researchmap

妊娠糖尿病合併妊婦における産後糖代謝異常リスクの検討

山田貴穂, 柳生田紀子, 西島浩二, 小川洋平, 谷内洋子, 吉原弘祐, 曽根博仁

糖尿病と妊娠 24 ( 2 ) S - 106 2024.8

Language：Japanese Publisher：(一社)日本糖尿病・妊娠学会

妊娠糖尿病(gestational diabetes mellitus:GDM)合併妊婦について、妊娠中のOGTTを含む指標から産後早期糖代謝異常のリスクが予測可能か検証した。当院で出産した単胎GDM妊婦を、産後OGTTの結果により正常型群と境界型以上群に分け、GDMの診断時期別(妊娠24週未満診断:E-GDM、妊娠24週以降診断:L-GDM)に、OGTTを含む妊娠中の各種指標を比較した。産後1年程度の間にGDMの約3割に耐糖能異常を生じ、境界型の割合はGDM診断時期による違いはなかった。E-GDMではGDM診断時OGTT120分値が高い場合、L-GDMでは妊娠中体重増加量が多い場合に産後の耐糖能異常を認めやすいことが判明した。(著者抄録)

researchmap

当院における周産期レジストリーを用いた妊娠糖尿病の転帰や予後の検討

柳生田紀子, 山田貴穂, 西島浩二, 有森直子, 小川洋平, 吉原弘祐, 曽根博仁

糖尿病と妊娠 24 ( 2 ) S - 102 2024.8

Language：Japanese Publisher：(一社)日本糖尿病・妊娠学会

2010～2020年に当院で周産期管理をした母児のデータベースを構築し、妊娠糖尿病(gestational diabetes mellitus:GDM)の転帰や予後を明らかにすることを目的とした。対象妊婦4385例とし、GDM群285例、対照群4100例で比較したところ対照群で周産期合併症が多かった。そこで併存疾患をもつ妊婦を除外した2240例で再解析を行い、GDM群では対照群と比較し妊娠高血圧症候群、羊水過多、heavy for dates(HFD)が有意に多い結果となった。再解析をしたことで、GDMによる周産期合併症のリスクは、併存疾患によるものより相対的に小さいことが示唆された。(著者抄録)

researchmap

重度糖尿病により帯状疱疹の全身性播種を来した1例

木村智佑, 間島貴之, 佐藤隆明, 鈴木浩史, 鈴木紗也佳, 佐藤もも, 加勢夕季乃, 河合亨, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( 7 ) 288 - 288 2024.7

Impact of health practice index and cardiovascular health metrics on incident cardiovascular disease according to glucose tolerance status.

Koshiro Murai, Kazuya Fujihara, Mayuko Harada Yamada, Yasuhiro Matsubayashi, Takaho Yamada, Midori Iwanaga, Masaru Kitazawa, Masahiko Yamamoto, Taeko Osawa, Yuta Yaguchi, Satoru Kodama, Hirohito Sone

Diabetology international 15 ( 3 ) 456 - 464 2024.7

Language：English Publishing type：Research paper (scientific journal)

AIMS: To evaluate and compare the association of incident cardiovascular disease (CVD) with the Health Practice Index (HPI) reflecting only lifestyle habits and Ideal Cardiovascular Health Metrics (ICVHMs) consisting of lifestyle habits and factors targeted for control in the same population according to glucose status. METHODS: This retrospective cohort study included 1,28,162 participants aged 18-72 years with no history of CVD followed for ≥ 3 years between 2008 and 2016. Participants were classified according to normal glucose tolerance (86,174), prediabetes (36,096), or diabetes (5892). HPI and ICVHMs scores were classified into three groups (high/medium/low). Multivariate Cox regression hazard analysis examined CVD risk. RESULTS: During a mean follow-up of 5.2 years, 1057 CVD events occurred. In prediabetes, CVD risk was significantly higher in groups with both medium and low HPI scores and ICVHMs scores compared to high scores for normal glucose tolerance (hazard ratios [HRs] for high/medium/low HPI scores were 0.95 [0.78-1.17], 1.56 [1.29-1.89], and 2.41 [1.74-3.34] and for ICVHMs scores were 0.74 [0.50-1.11], 1.58 [1.26-1.98], and 2.63 [2.10-3.31], respectively). Regarding diabetes, compared with high HPI/ICVHMs scores in the normal glucose tolerance group, a significantly increased CVD risk was observed in the high-score HPI group, but not in the high-score ICVHMs group (HPI high/medium/low HR, 1.63 [1.22-2.18], 2.19 [1.69-2.83], and 2.26 [1.34 -3.83]; ICVHMs high/medium/low HR, 1.14 [0.47-2.81], 2.38 [1.75-3.23], and 3.31 [2.50-4.38], respectively). CONCLUSIONS: In diabetes, ideal lifestyle practices alone were insufficient for primary prevention of CVD but had a greater impact on primary prevention of CVD in prediabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-024-00708-7.

DOI： 10.1007/s13340-024-00708-7

PubMed

researchmap

1666-P: Effect of Obesity in Family History (FH) on the Prevalence of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL)

IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, CHIKA HORIKAWA, SATORU KODAMA, EFREM D. FERREIRA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Heritability and obesity are strongly associated with the prevalence of T2DM, HT, and DL. We compared the effects of an FH of T2DM, HT, and DL combined with obesity on the prevalence of each in the same population. Of 41931 participants who underwent health checkups, the effects of an FH and BMI on the prevalence of those conditions were analyzed cross-sectionally. Prevalences of T2DM, HT, and DL were 5%, 20%, and 48%, respectively. Logistic regression analysis showed that ORs increased for all three as the number of FH positive cases increased and was most pronounced for T2DM. An FH of obesity and increased BMI were additively associated with the prevalence of the three diseases compared to BMI 20.0-21.9 and no positive FH (Fig. A). In addition, the combination of the number of family members with FH positivity (0,1, 2, ≥3) and obesity was additively associated with an increased FH of the three diseases compared to non-obesity and no FH of any of these diseases (Fig. B). For T2DM, the OR increased sharply in non-obese participants when the number of those with an FH of T2DM was ≥3 (14.4 [8.88-23.5]), but in obese participants the OR increased sharply when the number of those with an FH of T2DM was 2 (12.2 [8.85-16.9]) (Fig. B). Results suggest that, especially for T2DM, avoidance of obesity may be effective in reducing the prevalence of these disorders in those with many FH-positive family members.

 Disclosure

I. Ikeda: None. K. Fujihara: None. Y. Takeda: None. C. Horikawa: None. S. Kodama: None. E.D. Ferreira: None. Y. Mori: None. T. Kadowaki: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1666-p

researchmap

1148-P: Trajectories of Abnormalities in Metabolic Parameters in Japanese Adolescents and Young Adults

IZUMI IKEDA, KAZUYA FUJIHARA, HARUKA SHIOZAKI, SAKIKO Y. MORIKAWA, CHIKA HORIKAWA, YASUNAGA TAKEDA, HAJIME ISHIGURO, TAKAHO YAMADA, SATORU KODAMA, YOHEI OGAWA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Childhood obesity mostly transitions into adulthood and leads to non-communicable diseases such as type 2 diabetes and metabolic syndrome. We aimed to examine individual-level transitions in metabolic parameters during adolescence and young adulthood. We analyzed metabolic parameters in 523 participants (311 males) who underwent health examinations at the ages of 14 y (8th grade) and 20 y. Weight status was assessed by the International Obesity Task Force at 14 y and by BMI (thinness: &lt;18.5; normal: 18.5-24.9; obesity: ≥25.0) at 20 y. HbA1c ≥5.7% was defined as high. Clustered metabolic risk score (CMR) was calculated by summing the sex-age specific Z-scores of each metabolic factor (mean arterial pressure, non-HDLC, and HbA1c) with ≥1 SD defined as high. Among participants who were obese at 14 y, 56% of males and 29% of females remained obese at 20 y. In both sexes, 30-50% had high HbA1c and 30-50% had high CMR as tracked from adolescence to adulthood (table). Furthermore, the high CMR of obese females increased markedly from about 20% at 14 y to 50% at 20 y. In addition, 60% of females who were obese at both 14 y and 20 y had high HbA1c at 20 y. Results suggested the importance of lifestyle interventions from childhood, as about half of the high metabolic parameters observed in adolescents were tracked into adulthood, and obesity complications, which were rarely shown at 14 y, appeared in many at age 20 y.

 Disclosure

I. Ikeda: None. K. Fujihara: None. H. Shiozaki: None. S.Y. Morikawa: None. C. Horikawa: None. Y. Takeda: None. H. Ishiguro: None. T. Yamada: None. S. Kodama: None. Y. Ogawa: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1148-p

researchmap

1264-P: Impacts of Diabetes (DM) on Severe Functional Disability (FD) and Care-Need Level Deterioration in Japanese

IZUMI IKEDA, KAZUYA FUJIHARA, HARUKA SHIOZAKI, SAKIKO Y. MORIKAWA, KAHORI TSURUOKA, YAMASHITA YUKO, LAY MON KHIN, SIJIA WU, NORIKO YAGYUDA, CHIKA HORIKAWA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Avoidance of FD and the deterioration of care level needs leading to a decline in ADL and increased medical costs is urgent. We aimed to clarify the association between lifestyle habits, non-communicable diseases (i.e., DM, HT, and dyslipidemia) and their combinations and the incidence of severe FD and deterioration of the care-level. Followed for a median of 3.7 years were 9673 people who underwent health checkups. Care-level ≥2 (total assistance needed) indicates severe FD and worsening from the initial examination indicates deterioration. During the study period, 111 cases of severe FD occurred. Multivariate analysis showed that aging (per 5y) (OR 2.24 [1.95-2.56]), male (1.76 [1.16-2.66]), BMI&lt;18.5 (2.46 [1.40-4.35]), DM (1.81 [1.06-3.08]), HT (1.58 [1.05-2.38]), and lack of physical activity (PA) (2.17 [1.37-3.45]) were associated with severe FD. Prevalence of DM additively associated with severe FD. DM and ≥2 risk factors had a 10 times greater association than non-DM and no risk factor. Of 85 cases with worsening care needs, only DM was significantly associated with deterioration (2.88 [1.08-7.65]). DM is a significant risk factor for with double the increased risk of severe FD and triple care-need deterioration compared with those without DM. Also, in DM patients, low BMI, HT, and lack of PA greatly increased the risk of severe FD, suggesting the need for comprehensive treatment strategies.

 Disclosure

I. Ikeda: None. K. Fujihara: None. H. Shiozaki: None. S.Y. Morikawa: None. K. Tsuruoka: None. Y. Yuko: None. L. Khin: None. S. Wu: None. N. Yagyuda: None. C. Horikawa: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1264-p

researchmap

1372-P: Association between Fat Intake as the Percent of Total Energy and Incidence of Cardiovascular Disease in Persons with Type 2 Diabetes—Japan Diabetes Complication and Its Prevention Prospective Study (JDCP Study)

CHIKA HORIKAWA, MITSUYOSHI TAKAHARA, NAOTO KATAKAMI, YASUNAGA TAKEDA, MIZUKI TAKEUCHI, KAZUYA FUJIHARA, HIROAKI SUZUKI, NARIHITO YOSHIOKA, HITOSHI SHIMANO, JO SATOH, YASUAKI HAYASHINO, NAOKO TAJIMA, RIMEI NISHIMURA, YOSHIMITSU YAMASAKI, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Previous systematic reviews showed benefits of low-carbohydrate eating plans compared with low-fat eating plans in the treatment of diabetes (T2D) on parameters of cardiovascular disease (CVD) risk. However, studies on the relationship between fat intake as the % of total energy (F%E) and incidence of CVD in persons with T2D are insufficient. Therefore, we investigated this relationship as part of the JDCP study, a nationwide study launched in 2007. A total of 1477 persons with T2D aged 40-75 years completed a brief self-administered Diet History Questionnaire at baseline, and we analyzed the resultant data. Primary outcome was the 7-year risk of a CVD event. Hazard ratios for CVD according to quartiles of F%E (Q1-4) were estimated by Cox regression adjusted for confounders including sex, age, various laboratory tests, medication use, smoking history, drinking habits, physical activity, energy intake, protein intake, dietary fiber intake, and sodium intake. Mean F%E in Q1 to Q4 were 16.6%E, 21.8%E, 25.4%E, and 30.9%E, respectively. HbA1c, body mass index, triglycerides, and blood pressure were well controlled. No significant associations between F%E and incidence of CVD were shown for Q2, Q3, and Q4 relative to Q1 (Q2: 1.03 [95% CI, 0.47-2.28], Q3: 1.27 [0.58-2.76], and Q4: 1.10 [0.44-2.73]). Stratified analysis by sex and age also showed no significant difference between F%E and incidence of CVD. When %E from saturated fatty acids (SFA%E) was analyzed according to quartiles 1 and 4 SFA%E values were 4.9%E and 7.1%E, respectively. There were no significant differences in incidence of CVD among quartiles (Q1: Reference, Q2: 1.31 [0.66-2.61], Q3: 0.47 [0.18-1.25], and Q4: 1.02 [0.44-2.39]). Findings suggested that most Japanese with T2D during the study period consumed &lt; 30% of F%E and &lt;10% of SFA%E. No significant differences in incident CVD were observed within these ranges.

Disclosure

C. Horikawa: None. M. Takahara: None. N. Katakami: Speaker's Bureau; Abbott Japan Co., Ltd., Kowa Company, Ltd., MSD, Mitsubishi Tanabe Pharma Corporation, Lilly Diabetes, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Kyowa Kirin Co., Ltd., Daiichi Sankyo, Boehringer-Ingelheim, Sanofi. Y. Takeda: None. M. Takeuchi: None. K. Fujihara: None. H. Suzuki: Speaker's Bureau; Abbott Japan Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk, Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Boehringer-Ingelheim, Terumo Corporation, AstraZeneca, Bayer Inc., Kyowa Kirin Co., Ltd. N. Yoshioka: None. H. Shimano: None. J. Satoh: Speaker's Bureau; Lilly Diabetes, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Boehringer-Ingelheim. Y. Hayashino: Speaker's Bureau; Eli Lilly and Company, Merck & Co., Inc., Boehringer-Ingelheim, Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk A/S. N. Tajima: None. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation. Y. Yamasaki: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

Funding

The Japan Diabetes Society, the Japan Society for the Promotion of Science(23K10873).

DOI： 10.2337/db24-1372-p

researchmap

1474-P: Cross-Sectional and Longitudinal Relationships between Detailed Family History (FH) of Type 2 Diabetes Mellitus (T2DM), Hypertension (HT), and Dyslipidemia (DL) and Prevalence of Each Disorder

IZUMI IKEDA, KAZUYA FUJIHARA, YASUNAGA TAKEDA, MARIKO HATTA, SIJIA WU, SATORU KODAMA, YASUMICHI MORI, TAKASHI KADOWAKI, RITSUKO YAMAMOTO-HONDA, YASUJI ARASE, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

A FH of T2DM, HT, and DL are known risk factors; however, few studies have compared the impact of a FH of the 3 diseases in the same population. We examined the impact of a detailed FH of these conditions (i.e., in fathers, mothers, siblings and grandparents) on their prevalence and incidence in the study population. Data on 41,931 participants who underwent health checkups were examined and the results of a logistic regression and (Cox regression model in the same cohort were examined. Results of the cross-sectional study showed that odds ratios increased with the degree of a positive FH for all three diseases. Furthermore, in T2DM, the group with a three-generation positive FH was approximately 20 times larger than the control group which had no FH (Figure). In the longitudinal study, FH had a strong influence on the incidence of T2DM, HT, and DL, in that order, with a hazard ratio of 2.40 (1.93-2.98) for T2DM. A detailed FH was extremely useful for both quantitative screening for each disease and predicting the incidence of the three diseases, especially T2DM, for which a high risk was indicated in multiple generations with overlapping of positivity for a particular disease.

 Disclosure

I. Ikeda: None. K. Fujihara: None. Y. Takeda: None. M. Hatta: None. S. Wu: None. S. Kodama: None. Y. Mori: None. T. Kadowaki: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

DOI： 10.2337/db24-1474-p

researchmap

1259-P: Relationship between Number of Multiple Risk Factors and Functional Disability (FD) in Those With and Without Diabetes Mellitus (DM)

HARUKA SHIOZAKI, KAZUYA FUJIHARA, KAHORI TSURUOKA, IZUMI IKEDA, MASARU KITAZAWA, YASUHIRO MATSUBAYASHI, MASAHIKO YAMAMOTO, TAKAHO YAMADA, SATORU KODAMA, HIROHITO SONE

Diabetes 73 ( Supplement_1 ) 2024.6

Publishing type：Research paper (scientific journal) Publisher：American Diabetes Association

Although control of multiple risk factors is essential to prevent FD with and without DM, longitudinal studies are scarce that directly and quantitatively compare effects of such control. Thus, we assessed whether reaching multifactorial targets for HbA1c, blood pressure, non-HDLC, and lifestyle risks such as smoking and no physical activity are associated with FD in those with and without DM.

Enrolled were 9652 Japanese aged 39-98 y. FD was defined based on the Japanese long-term care insurance system, and targets were based on ADA and Japanese guidelines.

Of 8,861 non-DM persons, 6.3, 25.2 and 49.1% were on target for 0-2, 3 and 4 factors, respectively. Of 791 persons with DM, 12.4, 68.0 and 19.3% were on target for 0-2, 3-4 and 5 factors, respectively.

Multivariate Cox analysis showed increased FD with decreased targets reached regardless of DM (Table, upper). Compared with people with non-DM who achieved 4 targets, non-DM persons who achieved 0 to 2 targets and DM persons who achieved 3 to 4 targets had nearly twice the incidence of FD (Table, lower). Moreover, people with DM who achieved only 0 to 2 targets had an approximately 4 times higher incidence of FD (Table, lower). Control of modifiable risk factors was effective regardless of DM. Achievement of all 5 targets among people with DM may reduce FD to the same level as in non-DM persons who achieved all 4 targets.

 Disclosure

H. Shiozaki: None. K. Fujihara: None. K. Tsuruoka: None. I. Ikeda: None. M. Kitazawa: None. Y. Matsubayashi: None. M. Yamamoto: None. T. Yamada: None. S. Kodama: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Eisai Inc., Sumitomo Dainippon Pharma Co., Ltd.

Funding

the Japan Society for the Promotion of Science (21K11569); Daiwa Securities Health Foundation

DOI： 10.2337/db24-1259-p

researchmap

Reduced chondroitin sulfate content prevents diabetic neuropathy through transforming growth factor-β signaling suppression. International journal

Hajime Ishiguro, Takashi Ushiki, Atsuko Honda, Yasuhiro Yoshimatsu, Riuko Ohashi, Shujiro Okuda, Asami Kawasaki, Kaori Cho, Suguru Tamura, Tatsuya Suwabe, Takayuki Katagiri, Yiwei Ling, Atsuhiko Iijima, Tadahisa Mikami, Hiroshi Kitagawa, Akiyoshi Uemura, Kazunori Sango, Masayoshi Masuko, Michihiro Igarashi, Hirohito Sone

iScience 27 ( 4 ) 109528 - 109528 2024.4

Language：English Publishing type：Research paper (scientific journal)

Diabetic neuropathy (DN) is a major complication of diabetes mellitus. Chondroitin sulfate (CS) is one of the most important extracellular matrix components and is known to interact with various diffusible factors; however, its role in DN pathology has not been examined. Therefore, we generated CSGalNAc-T1 knockout (T1KO) mice, in which CS levels were reduced. We demonstrated that diabetic T1KO mice were much more resistant to DN than diabetic wild-type (WT) mice. We also found that interactions between pericytes and vascular endothelial cells were more stable in T1KO mice. Among the RNA-seq results, we focused on the transforming growth factor β signaling pathway and found that the phosphorylation of Smad2/3 was less upregulated in T1KO mice than in WT mice under hyperglycemic conditions. Taken together, a reduction in CS level attenuates DN progression, indicating that CS is an important factor in DN pathogenesis.

DOI： 10.1016/j.isci.2024.109528

PubMed

researchmap

Usefulness of New Criteria for Metabolic Syndrome Optimized for Prediction of Cardiovascular Diseases in Japanese.

Yurie Yamazaki, Kazuya Fujihara, Takaaki Sato, Mayuko Harada Yamada, Yuta Yaguchi, Yasuhiro Matsubayashi, Takaho Yamada, Satoru Kodama, Kiminori Kato, Hitoshi Shimano, Hirohito Sone

Journal of atherosclerosis and thrombosis 31 ( 4 ) 382 - 395 2024.4

Language：English Publishing type：Research paper (scientific journal)

AIMS: We attempted to clarify whether the multiple criteria for metabolic syndrome (MetS) can sufficiently predict cardiovascular disease, whether waist circumference (WC) should be required, and whether sex-specific thresholds for each component are necessary. Only a few large-scale studies among East Asians have addressed the ability of MetS to predict cardiovascular disease. METHODS: We analyzed the data of 330,051 men and 235,028 women aged 18-74 years with no history of coronary artery disease (CAD) or cerebrovascular disease (CVD) from a nationwide Japanese claims database accumulated during 2008-2016. The association of each MetS component with CAD or CVD (CAD/CVD), MetS associated with CAD/CVD according to various criteria, and utility of modified criteria with more specific optimal values for each component were examined using multivariate Cox regression and receiver operating characteristic (ROC) analysis. RESULTS: During the study, 3,934 men (1.19%) and 893 women (0.38%) developed CAD/CVD. For each current MetS criteria, there was a 1.3- to 2.9-fold increased risk of CAD/CVD. Optimal thresholds for predicting CAD/CVD were WCs of 83 and 77 cm, triglycerides levels of 130 and 90 mg/dl, high-density lipoprotein cholesterol levels of 50 and 65 mg/dl, blood pressures of 130/80 and 120/80 mmHg, and fasting plasma glucose levels of 100 and 90 mg/dl for men and women, respectively. The existing MetS criteria and modified criteria were not significantly different in predicting CAD/CVD, but using the modified criteria markedly increased the prevalence of MetS and percentage of people with MetS developing CAD/CVD. CONCLUSIONS: Although various criteria for MetS similarly predicted CAD/CVD, the new criteria greatly reduced the number of high-risk individuals, especially women, overlooked by the current criteria.

DOI： 10.5551/jat.64380

PubMed

researchmap

メタボリックシンドローム(MetS)の経年的変化と心血管疾患発症の関連

滝澤大輝, 藤原和哉, 三ツ間友里恵, 山田万祐子, 村井幸四郎, 佐藤隆明, 矢口雄大, 山本正彦, 大澤妙子, 北澤勝, 松林泰弘, 岩永みどり, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 249 2024.4

糖尿病(DM)の有無別にみた生活習慣関連因子(Cardiovascular Health Metrics)が腎透析導入(HD)に及ぼす影響の検討

大澤妙子, 藤原和哉, 山田万祐子, 矢口雄大, 佐藤隆明, 北澤勝, 松林泰弘, 山田貴穂, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 168 2024.4

糖尿病患者における重症合併症の複合アウトカム(CSDC)の発症リスク因子の検討

田中菜々子, 矢口雄大, 佐藤隆明, 大澤妙子, 鈴木浩史, 山田貴穂, 藤原和哉, 曽根博仁

糖尿病 67 ( Suppl.1 ) S - 186 2024.4

　 PREV - NEXT 　

<SONE, Hirohito>

Papers - SONE, Hirohito